{"id":"W2246741879","doi":"","title":"A phase I, pharmacological and biological study of weekly IMC-1121B, a recombinant human IgG1 monoclonal antibody (MAb), targeting vascular endothelial growth factor receptor 2 (VEGFR-2), in patients (pts) with advanced solid tumors.","year":2007,"lang":"en","type":"article","venue":"","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Pharmacodynamics; Pharmacokinetics; Cancer; Antibody; Internal medicine; Vascular endothelial growth factor; Angiogenesis; Pharmacology; Gastroenterology; Oncology; Immunology; VEGF receptors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001352034,0.00192629,0.001978599,0.0006661437,0.0005847589,0.001007884,0.001099454,0.001432007,0.002534913],"category_scores_gemma":[0.0008914126,0.0009173746,0.0009844552,0.0006451436,0.001352967,0.0009059915,0.0003722232,0.003825721,0.0008968723],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00119925,"about_ca_system_score_gemma":0.002068002,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001389574,"about_ca_topic_score_gemma":0.002426411,"domain_scores_codex":[0.9995333,0.0001869961,0.00001833584,0.0001061195,0.00004692166,0.000108303],"domain_scores_gemma":[0.9991309,0.0001099253,0.0001487081,0.0001121529,0.00006065914,0.0004376917],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4694126,0.2249926,0.008968661,0.001044952,0.0008840311,0.0004391274,0.0007436575,0.006351172,0.1664978,0.0005585403,0.005761438,0.1143454],"study_design_scores_gemma":[0.2334179,0.745047,0.009660888,0.0000230098,0.0002240411,0.0003187742,0.00005639054,0.001131247,0.006965789,0.0001680886,0.002960002,0.00002679119],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904393,0.001437489,0.001027661,0.0003717417,0.0001073794,0.003723613,0.001096148,0.0001464943,0.001650149],"genre_scores_gemma":[0.9862905,0.001349814,0.002490937,0.0006865911,0.0001757129,0.003904114,0.002239115,0.0000566286,0.00280665],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002534913,"threshold_uncertainty_score":0.008701205,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01535996579417292,"score_gpt":0.3167383054561219,"score_spread":0.301378339661949,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}